Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $52.45, for a total transaction of $865,425.00. Following the sale, the chairman now owns 53,014 shares in the company, valued at $2,780,584.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded up 1.75% during midday trading on Tuesday, hitting $53.94. 1,440,288 shares of the stock were exchanged. The company has a 50 day moving average price of $48.73 and a 200 day moving average price of $46.13. Ionis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $57.00. The firm’s market capitalization is $6.69 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The business had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. Ionis Pharmaceuticals’s revenue for the quarter was up 199.2% on a year-over-year basis. During the same period last year, the company posted ($0.52) EPS. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.37) EPS for the current year.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/07/18/ionis-pharmaceuticals-inc-nasdaqions-chairman-sells-865425-00-in-stock.html.

A number of research firms have commented on IONS. Cowen and Company restated a “market perform” rating on shares of Ionis Pharmaceuticals in a research report on Monday, May 22nd. BMO Capital Markets boosted their price target on shares of Ionis Pharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, May 11th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Wednesday, July 12th. Vetr downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating and set a $37.67 price target on the stock. in a research report on Monday, April 3rd. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $42.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, July 10th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.55.

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Ionis Pharmaceuticals by 37,569.7% in the first quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock worth $263,704,000 after buying an additional 6,542,394 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. Wellington Management Group LLP now owns 9,360,553 shares of the company’s stock valued at $376,295,000 after buying an additional 3,364,621 shares during the period. Norges Bank bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at approximately $50,976,000. State Street Corp increased its stake in shares of Ionis Pharmaceuticals by 20.5% in the first quarter. State Street Corp now owns 3,340,471 shares of the company’s stock valued at $134,285,000 after buying an additional 567,792 shares during the period. Finally, BB Biotech AG increased its stake in shares of Ionis Pharmaceuticals by 7.9% in the first quarter. BB Biotech AG now owns 7,461,295 shares of the company’s stock valued at $299,944,000 after buying an additional 548,123 shares during the period. Institutional investors and hedge funds own 88.72% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.